Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 4:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: conivaptan Clear all
Completed Phase 2 Interventional

Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart Failure

NCT00057356
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
conivaptan, placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
26
States / cities
Huntsville, Alabama • Los Angeles, California • Manteca, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Sep 3, 2026, 4:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare Conivaptan Pharmacokinetics in Subjects With Mild & Moderate Kidney Function Impairment to Subjects With Normal Kidney Function

NCT00887627
View directory record Official record
Conditions
Kidney Diseases, Hyponatremia
Interventions
conivaptan hydrochloride
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Sep 3, 2026, 4:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function

NCT00851227
View directory record Official record
Conditions
Liver Disease, Hyponatremia
Interventions
conivaptan hydrochloride
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
30 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Sep 3, 2026, 4:12 AM EDT
Withdrawn Phase 3 Interventional

Safety and Efficacy of Conivaptan for the Correction of Hyponatremia in Neurological Patients

NCT00684164
View directory record Official record
Conditions
Hyponatremia
Interventions
Conivaptan, D5
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 3, 2026, 4:12 AM EDT
Completed Phase 3 Interventional

An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic Hyponatremia

NCT00379847
View directory record Official record
Conditions
Hyponatremia
Interventions
conivaptan
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
7
States / cities
Tuscon, Arizona • Denver, Colorado • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Sep 3, 2026, 4:12 AM EDT
Not listed Not applicable Interventional

Comparing the Effects of Conivaptan and Diuretics on Plasma Neurohormones and Renal Blood Flow in Patients With Chronic Congestive Heart Failure

NCT00924014
View directory record Official record
Conditions
Heart Failure
Interventions
Conivaptan, Furosemide, Conivaptan and furosemide
Drug
Lead sponsor
Hennepin County Medical Center, Minneapolis
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 17, 2009 · Synced Sep 3, 2026, 4:12 AM EDT
Completed Phase 1 Interventional

Study of the Safety and Efficacy of Conivaptan (Vaprisol®) to Raise Serum Sodium Levels in Patients With Severe Traumatic Brain Injury

NCT00930202
View directory record Official record
Conditions
Severe Traumatic Brain Injury
Interventions
Conivaptan (Vaprisol)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 9, 2010 · Synced Sep 3, 2026, 4:12 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia

NCT01451411
View directory record Official record
Conditions
Hyponatremia
Interventions
Conivaptan hydrochloride, Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
2 Years to 17 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Sep 3, 2026, 4:12 AM EDT
Completed Phase 3 Interventional

Study of IV YM087 to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia

NCT00380575
View directory record Official record
Conditions
Hyponatremia
Interventions
YM087
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
27
States / cities
Mobile, Alabama • Phoenix, Arizona • Tuscon, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Sep 3, 2026, 4:12 AM EDT
Withdrawn Not applicable Interventional

Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular Failure

NCT00811486
View directory record Official record
Conditions
Right Heart Failure, Pulmonary Hypertension
Interventions
Spironolactone and conivaptan
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 27, 2013 · Synced Sep 3, 2026, 4:12 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia

NCT00478192
View directory record Official record
Conditions
Hyponatremia
Interventions
Conivaptan, Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
21
States / cities
Huntsville, Alabama • Tucson, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Sep 3, 2026, 4:12 AM EDT
Completed Phase 4 Interventional Results available

A Study of Multiple Dosing Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia

NCT00435591
View directory record Official record
Conditions
Hyponatremia, Euvolemia, Hypervolemia
Interventions
Conivaptan, placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Sep 3, 2026, 4:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan

NCT01370148
View directory record Official record
Conditions
Liver Disease
Interventions
conivaptan hydrochloride
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
30 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
3
States / cities
Anaheim, California • Lakewood, Colorado • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Sep 3, 2026, 4:12 AM EDT
Completed Phase 1 Interventional Results available

Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study

NCT03000283
View directory record Official record
Conditions
Cerebral Hemorrhage, Cerebral Edema, Intracerebral Hemorrhage, Stroke
Interventions
Conivaptan
Drug
Lead sponsor
Jesse Corry
Other
Eligibility
19 Years to 79 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Sep 3, 2026, 4:12 AM EDT